Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Torsdag 31 Oktober | 13:16:27 Europe / Stockholm

Svenska | English

BioStock

Saniona's CEO to BioStock: "SAN2355 is a highly promising candidate for commercialization"

2024-10-03 09:45:27

Saniona has announced significant progress in the preclinical development of the epilepsy drug candidate SAN2355 to treat focal-onset seizures. BioStock talked to CEO Thomas Feldthus to learn more.

Read the full interview with Thomas Feldthus at biostock.se:

https://www.biostock.se/en/2024/10/sanionas-ceo-san2355-is-a-highly-promising-candidate-for-commercialization/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden